

**Tremelimumab**

POSEIDON



### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments



### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: EMA: First-line treatment of tremelimumab in combination with durvalumab and platinum-based chemotherapy (ChT) for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations - FDA: Tremelimumab in combination with durvalumab and platinum-based ChT for adult patients with metastatic NSCLC with no EGFR mutation or ALK genomic tumor aberrations.  
Experimental Arm: Tremelimumab + Durvalumab and platinum-based ChT  
Control Arm: Platinum-based ChT



